Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374445 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL29374136 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL15819852 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL29371100 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL15821533 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL24121788 | 0.91 | LMNA (0.46) | — | |
| Maleic Acid SCHEMBL28863175 | 0.87 | DRD2 (0.52) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| Maleic Acid SCHEMBL28863174 | 0.87 | DRD2 (0.52) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL15818762 | 0.87 | DHFR (0.44) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL15818763 | 0.87 | DHFR (0.44) | DRD2DRD4DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| US-12473280-B2 | Substituted tricyclic compound as PRMT5 inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-20240287036-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-3768671-B1 | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2024-05-22 | — | — | EP | disclosed |
| EP-4352048-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2024-04-17 | — | — | EP | disclosed |
| US-20240116918-A1 | SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112645946-B | Substituted tricyclic compounds as PRMT5 inhibitors and application thereof | 南京圣和药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117480162-A | Compounds for the treatment or prophylaxis of PRMT5 mediated diseases | 阿古诺治疗有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2014100764-A2 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-1637140-B1 | Use of diphenylmethylpiperazine derivatives for the manufacture of a medicament for suppressing the proliferation of fibroblasts | KANEKO NOBORU (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1222924-B1 | ANTICANCER AGENTS | KANEKO NOBORU (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1637140-A1 | Use of diphenylmethylpiperazine derivatives for the manufacture of a medicament for suppressing the proliferation of fibroblasts | Kaneko, Noboru (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-6683083-B1 | USING LESS TOXIC AGENTS SUCH AS 1-(1-4-(DIPHENYLMETHYL)-PIPERAZINYL)-3-(1-(4-(4-CHLOROPHENYL)-4 -HYDROXY)PIPERIDINYL)-2-PROPANOL; INHIBITING FIBROBLAST PROLIFERATION | Kaneko, Noboru (JP) | 2004-01-27 | — | — | US | disclosed |
| EP-1222924-A1 | ANTICANCER AGENTS | Kaneko, Noboru (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-0541802-B1 | DIPHENYLMETHYLPIPERAZINE DERIVATIVE | KANEKO NOBORU (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5304558-A | Diphenylmethyl piperazine derivatives | KIRIN BREWERY CO., LTD. (JP) | 1994-04-19 | — | — | US | disclosed |
| EP-0541802-A1 | DIPHENYLMETHYLPIPERAZINE DERIVATIVE | KANEKO, Noboru (JP) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | DRD2 3403/4885DRD4 4122/4885DRD3 3776/4885 |
| US-12473280-B2 | Substituted tricyclic compound as PRMT5 inhibitor and use thereof | PRMT5, PRMT1, PRMT8 | DRD2 4817/4885DRD4 4812/4885DRD3 4826/4885 |
| US-20240287036-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | PRMT5, PRMT6, PRMT1 | DRD2 4685/4885DRD4 4671/4885DRD3 4695/4885 |
| US-20240116918-A1 | SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF | PRMT5, PRMT1, PRMT8 | DRD2 4817/4885DRD4 4812/4885DRD3 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.